33rd Medicinal Chemistry in Eastern England (Hatfield)

33rd Medicinal Chemistry in Eastern England

Event
33rd Medicinal Chemistry in Eastern England

Dates
Thursday, 28th April 2022

Place
Fielder Centre, Hatfield

Important links and downloads
Twitter hashtag – #HatfieldMedChem22
First announcement poster
Second announcement poster
To view RSC Covid-19 policy, click here

Synopsis
Known colloquially as the “Hatfield MedChem” meeting, this a highly successful, long-standing, one-day meeting which runs annually. The scientific program will comprise presentations showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics from the forefront of drug discovery of relevance to medicinal chemists.

Registration
Registration is now closed!

Registration fees:
RSC Member* £125
Non-member £175
RSC Student** Member* £55
Student** Non-member £95
Retired member* £20

* Member is a paid-up member of the RSC
** Student rates apply to undergraduate and post-graduate students only, but not post-doctoral students.

Want to become a member?
To join the RSC in order to qualify for discounted registration fees at all RSC, please follow this RSC link.

Student Bursaries
The RSC BMCS are offering some student bursaries to attend this meeting in person. Applications are open to PhD and post-doctoral applicants studying at academic institutions. Preference will be given to members of the RSC, a National Adhering Organisation of the EFMC, and any co-sponsoring organisation. The bursary value for this event is up to £300.

Applications for bursaries are now closed.

Exhibition/Sponsorship Opportunities
Bookings are now open, click here to book an exhibitor stand, or sponsor the meeting!

*Exhibitor Stands Fully Booked*

The Exhibitor Package is priced at £250 and includes:
– A six foot trestle table and chair(s);
– A blue baize table cloth;
– Access to electricity and Wi-fi;
– Logo inclusion in delegate handbook and rolling slides;
– Exhibitors promotional page in the printed delegate handbook.

£75 Exhibitor stand personal rate (no access to the technical sessions)
£120 Delegate pack inserts

We are also seeking sponsorship from organisations supporting the low registration fees offered to students. You can support and sponsor this meeting by clicking the booking link above.

Programme

9.00	Registration and refreshments
9.30	Morning Session Chair: Alison Jones, Charles River Welcome and Introduction
9.35	S01 The discovery of novel GPR52 agonists: HTL0041178, a potential therapy for schizoaffective and related psychiatric disorders Steve Watson, Heptares
10.10	S02 Discovery and development of first-in-class USP19 inhibitors for the treatment of metabolic and muscle-wasting disease Shane Rountree, Almac Discovery
10.45	Refreshments, Exhibition and Networking
11.10	S03 Development and characterisation of 2-imino-hexahydropyrimidin-4-one derived Plasmepsin X inhibitors with in vivo anti-malarial activity Teresa de Haro, UCB
11.45	S04 The Development of PROTACs at LifeArc Martin Ambler, Evotec
12.10	S05 Discovery and optimisation of allosteric inhibitors of Glutaminase 1 (GLS1) Mark Charles, Cancer Research UK
12.35	Lunch, Exhibition and Networking
13.30	S06 Afternoon Session Chair: Simon Ward, Medicines Discovery Institute, Cardiff University Capps Green Zomaya Award presentation lecture Applying AI: From Target Discovery through Drug Design to Patient Selection Jérémy Besnard, Exscientia
14.05	S07 Development of MAP4K4 Inhibitors for the Suppression of Cardiac Muscle Cell Death Nick Martin, Domainex
14.40	S08 Accelerating decision making through parallel med chem Neal Fazakerley, GSK
15.05	Refreshments, Exhibition and Networking
15.30	S09 Next generation estrogen receptor degraders (SERDs): A decade of discovery at AstraZeneca Samantha Hughes, AstraZeneca
16.05	S10 Discovery of novel LasB inhibitors as an inhaled antivirulence therapy for the treatment of Pseudomonas aeruginosa infections in patients with chronic respiratory disease David Davies, Antabio
16.30	S11 Discovery of DDU209: a potent and selective inhibitor of Lysyl tRNA synthesis Laura Cleghorn, Dundee Drug Discovery Unit, Univ Dundee
16.55	Concluding Remarks
17.00	Meeting close